Associated tags: Therapy, News, Pain, Health, Anxiety, Weight loss, Safety, Sleep, CPG, Cannabinoid, Chemistry, Food, SAN, Science, CBD, Coffee, Seed, CBG, Medical device, OBE, Pesticide, Research, Patient, Active, Antioxidant, Doctor of Philosophy, Nature, Chronic pain, THC, API
Locations: US, WEST VIRGINIA, WILLIAMSON, CURIA, CALIFORNIA, BIO
Retrieved on:
Thursday, February 29, 2024
Well,
SAN,
Mental health,
Woman,
Fortune 500,
Caregiver,
Nutrition,
Research,
Health,
Vitamin,
Female,
CPG,
Global health,
Food science,
Cannabinoid,
Harvard Business Review,
Empathy,
McKinsey & Company,
Wellness,
Health equity,
Science,
Public,
Management SAN FRANCISCO, Feb. 29, 2024 /PRNewswire/ -- Nalu Bio, a biotech company that is expanding health and wellness solutions through the development of no-high, chemistry-derived cannabinoid CPG ingredients, products, and therapeutic applications, proudly announces the appointment of Dondeena Bradley to its board of directors. With a distinguished career guiding health and wellness strategy, research and development, and wellbeing and nutrition-based innovations for the top global CPG companies, Dondeena brings invaluable expertise to drive an industry shift comparable to the introduction of vitamins 70 years ago—all while while closing the women's wellness gap—a $1 trillion opportunity to improve lives and economies globally.1
Key Points:
- "Dondeena brings valuable insights into CPG solution development and the pivotal stage for global health and wellness leaders' adoption of cannabinoids, making her an invaluable addition to our board," stated Caitlyn Krebs, Co-founder and CEO of Nalu Bio.
- Dondeena joins Nalu Bio as the third female board member, including co-founders Caitlyn Krebs (CEO) and Phyllis Whiteley (Chairman of the Board), who collectively bring decades of pharmaceutical and healthcare experience that drive impact.
- With Dondeena Bradley on its board, Nalu Bio is poised to lead the way in reshaping the future of consumer health and wellness.
- As the first company to offer AI-powered combinations of cannabinoids and bioactives, Nalu Bio continues to drive advancements designed to impact global CPG companies' innovation pipelines.
Retrieved on:
Thursday, February 8, 2024
Partnership,
Coffee,
Anxiety,
Traction,
SAN,
Vitamin,
Science,
AI,
PIPA,
Academic Medicine (journal),
Clinical trial,
Sleep,
Pain,
Safety,
Food,
Probiotic,
Caffeine,
Wellness,
Chemistry,
Cannabinoid,
CBD,
Global health,
Beauty,
CBN,
Vitamin C,
Health,
Aspirin,
Antioxidant,
CPG,
CBG,
Medical device SAN FRANCISCO, Feb. 8, 2024 /PRNewswire/ -- Nalu Bio, a biotech company specializing in no-high, chemistry-derived cannabinoids to address the top health and wellness challenges, today announced a first-of-its-kind partnership with PIPA, AI leader in Nutrition, Health and Wellness innovation to bring AI-enabled combinations of cannabinoids and bioactives to consumer packaged goods (CPG) companies. This partnership aims to create a new category of products at a time when market demand, cultural acceptance, and desire for cannabinoids are on the rise around the world.
Key Points:
- Nalu Bio is the first company to offer combinations of cannabinoids and bioactives to address pain, anxiety, sleep, and weight management.
- According to Nutrition Business Journal's 2023 Supplement Report, combination sales are expected to surpass single ingredient supplement sales this year.
- In tandem with PIPA, Nalu Bio will leverage predictive AI modeling to identify the optimal combinations of cannabinoids with unique bioactives such as vitamins, protein, fiber, antioxidants, probiotics, and superfoods.
- Like vitamins, not only can chemically-derived cannabinoid combinations address multiple health needs, but they can scale responsibly, safely, and sustainably.
Retrieved on:
Tuesday, October 26, 2021
Science,
OBE,
Pesticide,
Board of directors,
Research,
Seed,
Chemistry,
Active,
SAN,
Organization,
Partnership,
Patient,
CBD,
Risk,
Doctor of Philosophy,
Nature,
Board,
Chronic pain,
Multimedia,
THC,
Cannabinoid,
API,
Active ingredient,
Opioid,
CTO,
Fine chemical These partnerships will allow Nalu Bio to advance from research and development to commercial manufacturing, with supply chain excellence along the way.
Key Points:
- These partnerships will allow Nalu Bio to advance from research and development to commercial manufacturing, with supply chain excellence along the way.
- In addition, Nalu Bio has signed agreements with Curia Global to develop cannabinoid derivatives for therapeutic use as Active Pharmaceutical Ingredients (API) to address unmet medical needs.
- The establishment of a sophisticated and reliable global supply chain is a critical element in preparing for an efficient product launch from Day 1."
- At Nalu Bio , we learn from nature, and deliver through chemistry.
SAN FRANCISCO, May 25, 2021 /PRNewswire/ -- Nalu Bio, Inc., developers of a proprietary chemical synthesis platform that produces ultra-pure, consistently performing cannabinoids, announced today that opioid addiction expert Dr. Christopher "Dino" Beckett is now an advisor to the company.
Key Points:
- SAN FRANCISCO, May 25, 2021 /PRNewswire/ -- Nalu Bio, Inc., developers of a proprietary chemical synthesis platform that produces ultra-pure, consistently performing cannabinoids, announced today that opioid addiction expert Dr. Christopher "Dino" Beckett is now an advisor to the company.
- Dr. Beckett, who has been on the front lines of the opioid crisis for the last decade, is nationally recognized for his expertise in combating opioid addiction.
- Randall Ussery, Co-Founder of Nalu Bio, offered his personal insight into how the inherent inconsistency of hemp-based CBD can impact patients.
- Matthew Roberts, CTO of Nalu Bio, explained, "Nalu Bio is committed to enabling the better treatment of major medical challenges like addiction, pain management, and mental health issues.
The collaboration with Prof. Mackie aims to demonstrate that synthetic CBD has the same potency and efficacy as plant-derived CBD.
Key Points:
- The collaboration with Prof. Mackie aims to demonstrate that synthetic CBD has the same potency and efficacy as plant-derived CBD.
- We are very excited to be working with these distinguished scientists to help us realize the full therapeutic potential of synthetic cannabinoids.
- We are especially pleased to welcome Ken to our Advisory Board," said Caitlyn Krebs, Co-Founder & CEO of Nalu Bio.
- Nalu Bio is creating a new category of cannabinoids and wellness ingredients which will offer great therapeutic promise for the treatment of pain management and opioid addiction.
